cgmp fda No Further a Mystery
No. 21 CFR 211.113(a) involves appropriate prepared treatments to be recognized and adopted during manufacturing to stop objectionable microorganisms in drug solutions not required to be sterile. Furthermore, the next paragraph of USP Standard Chapter Antimicrobial Efficiency Testing reads: Antimicrobial preservatives should not be employe